argenx SE (ARGX)
| Market Cap | 57.28B +63.8% |
| Revenue (ttm) | 5.32B +70.3% |
| Net Income | 1.72B +33.9% |
| EPS | 26.21 +39.8% |
| Shares Out | 62.54M |
| PE Ratio | 33.40 |
| Forward PE | 26.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 162,203 |
| Open | 915.84 |
| Previous Close | 918.22 |
| Day's Range | 892.93 - 919.16 |
| 52-Week Range | 590.78 - 953.58 |
| Beta | -0.02 |
| Analysts | Buy |
| Price Target | 1,081.96 (+20.41%) |
| Earnings Date | Jul 23, 2026 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for ARGX stock is "Buy." The 12-month stock price target is $1,081.96, which is an increase of 20.41% from the latest price.
News
After Forte acquisition, H.C. Wainwright says First Tracks could be target
After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a 43% premium to Friday’s share price and a total equity value of…
Forte Biosciences downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Forte Biosciences (FBRX) to In Line from Outperform with a price target of $77, up from $69, after Argenx (ARGX) agreed to acquire Forte for $77 per…
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102
argenex NASDAQ: ARGX said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for aut...
ARGX Maintained by Baird -- Price Target Raised to $932
ARGX Maintained by Baird -- Price Target Raised to $932
M&A News: Forte Biosciences Shares Leap 40% After Argenx Seals $2.2B Immunology Deal
Shares in Forte Biosciences ($FBRX) were 40% healthier in pre-market trading today after it was bought by peer Argenx ($ARGX) for $2.2 billion. Multiple Autoimmune Conditions Dutch immunology innovati...
argenx SE Transcript: M&A announcement
The acquisition brings a first-in-class anti-CD122 antibody, FB102, into the immunology pipeline, targeting large unmet needs in vitiligo and celiac disease, with potential for broader autoimmune indications. The $2.2B cash deal leverages proven development and commercialization strategies to maximize impact and supports long-term growth ambitions.
argenx SE Press release: M&A announcement
argenx SE issued a press release on July 27, 2026, disclosing material business information to investors.
argenx SE Slides: M&A announcement
argenx SE has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
Argenx price target raised to $932 from $867 at Baird
Baird raised the firm’s price target on Argenx (ARGX) to $932 from $867 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results which…
Forte Biosciences (FBRX) Soars 39% on Acquisition by Argenx
Forte Biosciences (FBRX) Soars 39% on Acquisition by Argenx
Argenx (ARGX) to Acquire Forte Biosciences for $2.2 Billion
Argenx (ARGX) to Acquire Forte Biosciences for $2.2 Billion
argenx SE (ARGX) to Acquire Forte Biosciences (FBRX) for $2.2B
argenx SE (ARGX) to Acquire Forte Biosciences (FBRX) for $2.2B
Argenx to acquire Forte Biosciences for $77 per share in cash
Argenx (ARGX) and Forte (FBRX) announced that the companies have entered into a definitive agreement under which Argenx will acquire Forte Biosciences for $77 per share in cash, representing a…
Argenx To Acquire Forte For Approx. $2.2 Bln To Expand Immunology Pipeline; Forte Shares Soar
(RTTNews) - Argenx (ARGX), an immunology company, and Forte Biosciences, Inc. (FBRX),a clinical-stage biopharmaceutical company on Monday announced that they have entered into a definitive agreement u...
Argenx Acquires Forte Biosciences for $2.2 Billion, Expanding Pipeline
Argenx Acquires Forte Biosciences for $2.2 Billion, Expanding Pipeline
Argenx to Buy Forte Biosciences for $2.2 Billion
The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
Argenx to buy Forte Biosciences for about $2.2 billion
Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
Transaction builds on argenx's prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in v...
ARGX Maintains Rating by Oppenheimer -- Price Target Raised to $1037
ARGX Maintains Rating by Oppenheimer -- Price Target Raised to $1037
ARGX Maintained by RBC Capital -- Price Target Raised to $1025
ARGX Maintained by RBC Capital -- Price Target Raised to $1025
Argenx price target raised to $1,203 from $1,182 at Citi
Citi raised the firm’s price target on Argenx (ARGX) to $1,203 from $1,182 and keeps a Buy rating on the shares.
Argenx price target raised to $950 from $900 at Barclays
Barclays raised the firm’s price target on Argenx (ARGX) to $950 from $900 and keeps an Overweight rating on the shares.
ARGX Maintained by Guggenheim -- Price Target Raised to $1185
ARGX Maintained by Guggenheim -- Price Target Raised to $1185
ARGX Maintained by Citizens -- Price Target Lowered to $932
ARGX Maintained by Citizens -- Price Target Lowered to $932
Argenx price target raised to $1,200 from $1,180 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Argenx (ARGX) to $1,200 from $1,180 and keeps an Overweight rating on the shares after the company reported Q2 revenues “meaningfully above…